Japanese kids get extended access to heart drug in safety study
NCT ID NCT06149104
Summary
This study monitored the safety of sacubitril/valsartan, a heart failure medication, in 8 Japanese children who had completed a previous trial. It allowed these children to continue receiving the medication while researchers tracked any side effects. The goal was to provide continued treatment access until a pediatric version became commercially available in Japan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ōbu, Aichi-ken, 474 8710, Japan
-
Novartis Investigative Site
Ōmura, Nagasaki, 856-8562, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113 8655, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 157-8535, Japan
-
Novartis Investigative Site
Saitama, 330 8777, Japan
-
Novartis Investigative Site
Toyama, 930-0194, Japan
Conditions
Explore the condition pages connected to this study.